Literature DB >> 10370906

Parkinson's disease--a multifactorial neurodegenerative disorder.

O Riess1, R Krüger.   

Abstract

The pathogenesis of idiopathic Parkinson's disease (PD) is not known, but is thought to be multifactorial, deriving from environmental factors acting on genetically predisposed individuals with aging. Association studies of DNA polymorphisms are able to detect a genetic background predisposing to PD. Mechanisms as oxidative stress, xenobiotica toxicity and altered dopamine metabolism might lead to a selective cell death of most vulnerable nerve cells and represent the primary subject to be studied by DNA analysis. Furthermore, protein aggregation is likely to be a major cause for the disease. Recently it has been shown that alpha-synuclein is accumulated in Lewy bodies of sporadic PD and mutated in some rare families with an autosomal dominant trait of the disease (ADPD). The identification of further genes responsible for PD will subsequently lead to first insights into the pathogenesis of one of the most common neurodegenerative disorders in humans.

Entities:  

Mesh:

Year:  1999        PMID: 10370906     DOI: 10.1007/978-3-7091-6360-3_6

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  9 in total

1.  Inhibition of amyloid fibrillogenesis and toxicity by a peptide chaperone.

Authors:  Puttur Santhoshkumar; Krishna K Sharma
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

2.  GSTpi expression in MPTP-induced dopaminergic neurodegeneration of C57BL/6 mouse midbrain and striatum.

Authors:  Margarida Castro-Caldas; Andreia Neves Carvalho; Isabel Peixeiro; Elsa Rodrigues; Maria Celeste Lechner; Maria João Gama
Journal:  J Mol Neurosci       Date:  2008-09-16       Impact factor: 3.444

Review 3.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

4.  Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson's Disease Patients.

Authors:  Andrés Felipe Duque; Juan Carlos Lopez; Bruno Benitez; Helena Hernandez; Juan José Yunis; William Fernandez; Humberto Arboleda; Gonzalo Arboleda
Journal:  Colomb Med (Cali)       Date:  2015-09-30

5.  Tracking Parkinson's: Study Design and Baseline Patient Data.

Authors:  Naveed Malek; Diane M A Swallow; Katherine A Grosset; Michael A Lawton; Sarah L Marrinan; Alexander C Lehn; Catherine Bresner; Nin Bajaj; Roger A Barker; Yoav Ben-Shlomo; David J Burn; Thomas Foltynie; John Hardy; Huw R Morris; Nigel M Williams; Nicholas Wood; Donald G Grosset
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

6.  Multi-Target Protective Effects of Gintonin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Mediated Model of Parkinson's Disease via Lysophosphatidic Acid Receptors.

Authors:  Jong Hee Choi; Minhee Jang; Seikwan Oh; Seung-Yeol Nah; Ik-Hyun Cho
Journal:  Front Pharmacol       Date:  2018-05-23       Impact factor: 5.810

Review 7.  Food Contamination: An Unexplored Possible Link between Dietary Habits and Parkinson's Disease.

Authors:  Giulia Caioni; Annamaria Cimini; Elisabetta Benedetti
Journal:  Nutrients       Date:  2022-03-31       Impact factor: 5.717

Review 8.  Exploring the multifactorial aspects of Gut Microbiome in Parkinson's Disease.

Authors:  Sujith Pavan; Arvind N Prabhu; Sankar Prasad Gorthi; Bhabatosh Das; Ankur Mutreja; Vignesh Shetty; Thandavarayan Ramamurthy; Mamatha Ballal
Journal:  Folia Microbiol (Praha)       Date:  2022-05-18       Impact factor: 2.629

9.  Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.

Authors:  Rodolphe Hajj; Aude Milet; Damien Toulorge; Nathalie Cholet; Julien Laffaire; Julie Foucquier; Sandra Robelet; Richard Mitry; Mickael Guedj; Serguei Nabirotchkin; Ilya Chumakov; Daniel Cohen
Journal:  Sci Rep       Date:  2015-11-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.